How the Hepatitis C
Elimination Plan Works
The subscription model is an innovative drug pricing and payment mechanism to enable Louisiana to dramatically expand access to Hepatitis C treatment within its Medicaid and incarcerated populations. Louisiana selected Asegua Therapeutics of Gilead Sciences, Inc. as its pharmaceutical partner.
Asequa will provide unrestricted access to the authorized generic for Epclusa for Medicaid eligible and incarcerated Louisianans for 5 years. Our goal is to cure at least 10,000 Medicaid-enrolled and incarcerated individuals by 2020.